Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen.
Eleven patients with hyperlipoproteinemia (HLP) type II A, were treated for 3 months with a new compound, a phenoxy-isobuturic acid derivative, procetofen, at a dosage of 100 mg t.i.d. Mean plasma cholesterol decreased after 3 months by 25% from a pretreatment value of 10.3 +/- 0.7 mmol/l (p less than 0.001). The reduction of plasma cholesterol was apparently due not only to a decrease in LDL, as expressed from a marked reduction (15%) of the major LDL apolipoprotein moiety, apolipoprotein B, but also presumably to a decrease in VLDL as reflected from a marked reduction (45%, p less than 0.05) in plasma triglycerides. Furthermore, a marked favourable increase (28%, p less than 0.001) in HDL major apolipoprotein moiety, apolipoprotein A, was observed. No disagreeable side-effects were recorded, except for a skin rash in one patient.